Financial Wire

澳交所前瞻:受中東緊張局勢提振,油價飆升,澳洲股市可望上漲;力拓集團公佈第一季銅當量和鐵礦石產量均有所成長。

-- 受全球油價上漲提振,澳洲股市週二可望走高。此前,由於中東緊張局勢再升級,以及美伊停火談判陷入僵局導致霍爾木茲海峽局勢不確定性加劇,布蘭特原油價格飆升超過5%。 隔夜,標普500指數、那斯達克指數和道瓊工業指數分別下跌0.2%、0.3%和0.01%。 宏觀經濟方面,澳新銀行週二公佈的數據顯示,4月13日至19日當週,澳新銀行-羅伊摩根澳洲消費者信心指數下降0.2點至64.3。 企業方面,力拓集團(ASX:RIO)週二公佈,第一季銅當量產量年增9%,而全球鐵礦石產量增加12%至8,280萬噸。 萊納斯稀土公司(ASX:LYC)表示,其第三財季總銷售收入從去年同期的1.23億澳元增至2.65億澳元,銷售額也從1.246億澳元增至2.34億澳元。 澳洲基準股指週一上漲0.1%,或6.4點,收在8953.30點。

Related Articles

Asia

Huadian New Energy 2025 Profit Down 18%, Revenue Up 15%

Huadian New Energy (SHA:600930) posted 2025 attributable net profit of 7.26 billion yuan, down 18% from 8.83 billion yuan the previous year.Earnings per share slipped to 0.18 yuan from 0.24 yuan, according to a filing with the Shanghai bourse.Operating revenue rose 15% year over year to 39.0 billion yuan from 34.0 billion yuan.Shares of the power company were down 1% in recent trade.

$SHA:600930
Asia

National Storage REIT Says New South Wales Court Approves Brookfield, GIC Takeover Scheme

National Storage REIT (ASX:NSR) confirmed that the Supreme Court of New South Wales has approved the share scheme of arrangement and granted judicial advice for the trust scheme, enabling a Brookfield Funds and GIC-led consortium to proceed with the acquisition of all the company stapled securities, according to a Tuesday Australian bourse filing.The schemes are now legally effective following lodgment with the Australian Securities and Investments Commission, and the company's securities are expected to be suspended from trading at the close of trading on Tuesday, per the filing.The scheme record date is April 29, with implementation scheduled for May 8, when security holders will receive the scheme consideration, the filing added.

$ASX:NSR
Asia

Starpharma Says US FDA Supports First-in-Human Study of Cancer Radiotherapy Candidate; Shares Gain 7%

Starpharma Holdings (ASX:SPL) has received positive feedback from the US Food and Drug Administration (FDA) on the proposed design of its first-in-human phase 1 clinical study of the DEP HER2 radiotherapy candidate, according to a Tuesday filing with the Australian bourse.The company is developing the candidate to treat certain gastric/gastro-oesophageal junction cancers and other advanced cancers in patients who have previously received targeted therapy.The US FDA feedback supports plans to launch the phase one study, which is on track to begin in the second half of the year.The FDA also confirmed that the radiotherapy candidate is targeting a population with a significant unmet medical need, indicating the potential for a fast-track designation or other accelerated development pathways, Starpharma said.The company's shares were 7% higher in recent Tuesday trade.

$ASX:SPL